Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (83)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ness, R. B.
Right arrow Articles by Wu, A. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ness, R. B.
Right arrow Articles by Wu, A. H.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

American Journal of Epidemiology Vol. 155, No. 3 : 217-224
Copyright © 2002 by The Johns Hopkins University School of Hygiene and Public Health


ORIGINAL CONTRIBUTIONS

Infertility, Fertility Drugs, and Ovarian Cancer: A Pooled Analysis of Case-Control Studies

Roberta B. Ness1, Daniel W. Cramer2, Marc T. Goodman3, Susanne Krûger Kjaer4, Kathy Mallin5, Berit Jul Mosgaard6, David M. Purdie7, Harvey A. Risch8, Ronald Vergona1 and Anna H. Wu9

1 University of Pittsburgh School of Public Health, Pittsburgh, PA.
2 Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
3 Cancer Research Center, University of Hawaii, Honolulu, HI.
4 Danish Cancer Society, Institute of Cancer Epidemiology, Copenhagen, Denmark.
5 University of Illinois at Chicago, Chicago, IL.
6 Department of Obstetrics and Gynecology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.
7 Queensland Institute of Medical Research, Royal Brisbane Hospital, Queensland, Australia.
8 Yale University School of Medicine, New Haven, CT.
9 University of Southern California, Los Angeles, CA.

Controversy surrounds the relations among infertility, fertility drug use, and the risk of ovarian cancer. The authors pooled interview data on infertility and fertility drug use from eight case-control studies conducted between 1989 and 1999 in the United States, Denmark, Canada, and Australia. Odds ratios and 95% confidence intervals were calculated, adjusting for age, race, family history of ovarian cancer, duration of oral contraception use, tubal ligation, gravidity, education, and site. Included in the analysis were 5,207 cases and 7,705 controls. Among nulligravid women, attempts for more than 5 years to become pregnant compared with attempts for less than 1 year increased the risk of ovarian cancer 2.67-fold (95% confidence interval (CI): 1.91, 3.74). Among nulliparous, subfertile women, neither any fertility drug use (odds ratio (OR) = 1.60, 95% CI: 0.90, 2.87) nor more than 12 months of use (OR = 1.54, 95% CI: 0.45, 5.27) was associated with ovarian cancer. Fertility drug use in nulligravid women was associated with borderline serous tumors (OR = 2.43, 95% CI: 1.01, 5.88) but not with any invasive histologic subtypes. Endometriosis (OR = 1.73, 95% CI: 1.10, 2.71) and unknown cause of infertility (OR = 1.19, 95% CI: 1.00, 1.40) increased cancer risk. These data suggest a role for specific biologic causes of infertility, but not for fertility drugs in overall risk for ovarian cancer.

fertility agents, female; infertility; ovarian neoplasms

Abbreviations: CI, confidence interval; OR, odds ratio


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Reproductive SciencesHome page
P. A. W. Rogers, T. M. D'Hooghe, A. Fazleabas, C. E. Gargett, L. C. Giudice, G. W. Montgomery, L. Rombauts, L. A. Salamonsen, and K. T. Zondervan
Priorities for Endometriosis Research: Recommendations From an International Consensus Workshop
Reproductive Sciences, April 1, 2009; 16(4): 335 - 346.
[Abstract] [PDF]


Home page
BMJHome page
A. Jensen, H. Sharif, K. Frederiksen, and S. K. Kjaer
Use of fertility drugs and risk of ovarian cancer: Danish population based cohort study
BMJ, February 5, 2009; 338(feb05_2): b249 - b249.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
P. M Webb
Fertility drugs and ovarian cancer
BMJ, February 5, 2009; 338(feb05_2): a3075 - a3075.
[Full Text]


Home page
Hum ReprodHome page
G. Chene, F. Penault-Llorca, G. Le Bouedec, F. Mishellany, M.M. Dauplat, P. Jaffeux, B. Aublet-Cuvelier, J.L. Pouly, P. Dechelotte, and J. Dauplat
Ovarian epithelial dysplasia after ovulation induction: time and dose effects
Hum. Reprod., January 1, 2009; 24(1): 132 - 138.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
A. Jensen, H. Sharif, J. H. Olsen, and S. K. Kjaer
Risk of Breast Cancer and Gynecologic Cancers in a Large Population of Nearly 50,000 Infertile Danish Women
Am. J. Epidemiol., July 1, 2008; 168(1): 49 - 57.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
A. Melin, P. Sparen, and A. Bergqvist
The risk of cancer and the role of parity among women with endometriosis
Hum. Reprod., November 1, 2007; 22(11): 3021 - 3026.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
S. S. Tworoger, K. M. Fairfield, G. A. Colditz, B. A. Rosner, and S. E. Hankinson
Association of Oral Contraceptive Use, Other Contraceptive Methods, and Infertility with Ovarian Cancer Risk
Am. J. Epidemiol., October 15, 2007; 166(8): 894 - 901.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
J.-H. Choi, A. S. T. Wong, H.-F. Huang, and P. C. K. Leung
Gonadotropins and Ovarian Cancer
Endocr. Rev., June 1, 2007; 28(4): 440 - 461.
[Abstract] [Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
G. D. Aletti, M. M. Gallenberg, W. A. Cliby, A. Jatoi, and L. C. Hartmann
Current Management Strategies for Ovarian Cancer
Mayo Clin. Proc., June 1, 2007; 82(6): 751 - 770.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
H. Mertes and G. Pennings
Oocyte donation for stem cell research
Hum. Reprod., March 1, 2007; 22(3): 629 - 634.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
C. Basille, F. Olivennes, J. Le Calvez, N. Beron-Gaillard, G. Meduri, C. Lhomme, P. Duvillard, J. Benard, and P. Morice
Impact of gonadotrophins and steroid hormones on tumour cells derived from borderline ovarian tumours
Hum. Reprod., December 1, 2006; 21(12): 3241 - 3245.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
A. Melin, P. Sparen, I. Persson, and A. Bergqvist
Endometriosis and the risk of cancer with special emphasis on ovarian cancer
Hum. Reprod., May 1, 2006; 21(5): 1237 - 1242.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
W. J. Murdoch
Carcinogenic Potential of Ovulatory Genotoxicity
Biol Reprod, October 1, 2005; 73(4): 586 - 590.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
J. B. Greer, F. Modugno, G. O. Allen, and R. B. Ness
Short-Term Oral Contraceptive Use and the Risk of Epithelial Ovarian Cancer
Am. J. Epidemiol., July 1, 2005; 162(1): 66 - 72.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
G. L. Gierach, F. Modugno, and R. B. Ness
Relations of Gestational Length and Timing and Type of Incomplete Pregnancy to Ovarian Cancer Risk
Am. J. Epidemiol., March 1, 2005; 161(5): 452 - 461.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
A. Lukanova and R. Kaaks
Endogenous Hormones and Ovarian Cancer: Epidemiology and Current Hypotheses
Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 98 - 107.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
S. A. Cannistra
Cancer of the Ovary
N. Engl. J. Med., December 9, 2004; 351(24): 2519 - 2529.
[Full Text] [PDF]


Home page
Am J EpidemiolHome page
M. A. Rossing, M.-T. C. Tang, E. W. Flagg, L. K. Weiss, and K. G. Wicklund
A Case-Control Study of Ovarian Cancer in Relation to Infertility and the Use of Ovulation-inducing Drugs
Am. J. Epidemiol., December 1, 2004; 160(11): 1070 - 1078.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. M. Cottreau, R. B. Ness, F. Modugno, G. O. Allen, and M. T. Goodman
Endometriosis and Its Treatment with Danazol or Lupron in Relation to Ovarian Cancer
Clin. Cancer Res., November 1, 2003; 9(14): 5142 - 5144.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
K.-H. Tung, M. T. Goodman, A. H. Wu, K. McDuffie, L. R. Wilkens, L. N. Kolonel, A. M. Y. Nomura, K. Y. Terada, M. E. Carney, and L. H. Sobin
Reproductive Factors and Epithelial Ovarian Cancer Risk by Histologic Type:A Multiethnic Case-Control Study
Am. J. Epidemiol., October 1, 2003; 158(7): 629 - 638.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
F. Lubin, A. Chetrit, L. S. Freedman, E. Alfandary, Y. Fishler, H. Nitzan, A. Zultan, and B. Modan
Body Mass Index at Age 18 Years and during Adult Life and Ovarian Cancer Risk
Am. J. Epidemiol., January 15, 2003; 157(2): 113 - 120.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
P. Doyle, N. Maconochie, V. Beral, A. J. Swerdlow, and S.L. Tan
Cancer incidence following treatment for infertility at a clinic in the UK
Hum. Reprod., August 1, 2002; 17(8): 2209 - 2213.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
Stay out of the hospital! Wherever you are in the world...
Ann. Onc., April 1, 2002; 13(4): 495 - 498.
[Full Text] [PDF]


Home page
JWatch Women's HealthHome page
Infertility Drugs and Ovarian Cancer: No Evidence of Association
Journal Watch Women's Health, March 5, 2002; 2002(305): 7 - 7.
[Full Text]


Home page
JWatch GeneralHome page
Infertility Drugs and Ovarian Cancer: No Evidence of Association
Journal Watch (General), February 22, 2002; 2002(222): 6 - 6.
[Full Text]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.